Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
-Fixed - dose combination of ASC30 and ASC39 (ASC30_39 FDC) tablets, dosed orally in dogs, demonstrated comparable pharmacokinetics to those observed in their respective monotherapies in a head-to-head study . The fixed dose combination had...
SK bioscience, MSD, and Hilleman Laboratories Advance Zaire ebolavirus Vaccine Development with CEPI Funding
CEPI to provide up to USD 30 million to support development of MSD's Zaire ebolavirus vaccine Collaboration addresses manufacturing complexity and cold-chain challenges to improve yield and thermostability Partnership aims to expand affordable and...